Miguel A. Villalona‐Calero

Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.

Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer.

The Impact of Medicaid Expansion on Stage at Diagnosis of Melanoma Patients: A Retrospective Study.

Supplementary Figure S1 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Table S1 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S4 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Data from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S5 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S2 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S4 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S1 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S5 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S6 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S2 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Table S1 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S3 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Data from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S6 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Supplementary Figure S3 from Preclinical Evaluation of Off-The-Shelf PD-L1<sup>+</sup> Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer

Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience.

Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.

Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States.

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma

CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors